RVBA-PFIZEPharma Manufacturing

Pfizer — in detail

Full extracted data, every event in the company's history we've captured, and (soon) external news. The full ratios diagnostic with peer benchmarks lives at /ratios.

Reference sources (3/5)

Source documents
Recent disclosure
Multi-year metrics
Targets
Certifications

External news

No ESG-relevant news ingested yet for this company. Run python -m pipeline.news_gdelt to backfill. Sourced from GDELT 2.0 (3-month trailing window).

Data by year· every metric + key events per year

Each year shows the firm's reported metrics on the left and the most material events on the right. Up to 10 events per year; the full event log is one click further.

2025

cdp response ↗

no metric rows for this year

2024

sustainability report ↗

Climate · carbon footprint (tCO2e)

Scope 1	613,218
Scope 2 (market-based)	465,128
Scope 3	3.6M
Cat 1 · Purchased goods	2.8M
Cat 2 · Capital goods	119,357
Cat 3 · Fuel + energy	254,803
Cat 4 · Upstream transport	154,000
Cat 5 · Waste in operations	5,435
Cat 6 · Business travel	188,000
Cat 7 · Employee commuting	20,564
Cat 8 · Upstream leased	15,511
Cat 9 · Downstream transport	3,397
Cat 10 · Processing of sold	0
Cat 11 · Use of sold products	0
Cat 12 · End-of-life	0
Cat 13 · Downstream leased	0
Cat 14 · Franchises	0
Cat 15 · Investments	7,342
Gross carbon footprint	4.6M
Offsets retired	-0
Net carbon footprint	4.6M

Energy (kWh)

Electricity	1.2B
Fuel (stationary + mobile)	3B
Heat / steam	194M
Total energy	4.4B
Renewable energy	(267.2M)
Non-renewable / hydrocarbon	4.2B
Renewable electricity %	14%

Nature

water withdrawal m3	30.9Mm³
water consumption m3	3.3Mm³
waste generated t	121,740tonnes
waste hazardous t	79,900tonnes
waste recycled t	32,300tonnes

Social

h s total recordable injury rate	0per 100 employees
h s lost time injury rate	0per 100 employees
h s fatalities	2count
employee turnover pct	6%
gender pay gap median pct	-2%
workforce board female pct	23%

Governance

internal carbon price usd per tco2eⓘ	50USD per tCO2e
audit assurance climate levelⓘ	2scale 0-2
esg linked executive pay yn	1yes/no
board diversity pct	31%
board independence pct	92%

P&L highlights (USD)

Headcount (FTE)	81,000people
Revenue	63.6B
Cost of revenue	(21.8B)
Gross profit	41.8B
Operating expenses (S&M + G&A)	(25.4B)
Operating income	16.5B
Net income	8B

Balance sheet highlights (USD)

Property, plant & equipment	18.4B
Total assets	213.4B
Total debt	64.4B
Cash & equivalents	1B
Minority interest	294M

Market & shares

Market cap (FY-end)	150.3B
Shares outstanding	5.7B

Events 2024· 51

3R Circular Program and reusable packaging initiative

3R Circular Program prioritizes reduction, reuse, and recycling of high-volume shipment materials (e.g., reusing thermal blankets). Global Circularity Project testing feasibility of reusing packaging in downstream transportation, replacing single-use systems with reusable solutions.

▾ expand

No explicit durable carbon removals portfolio disclosed

The 2024 Impact Report does not disclose use of durable carbon removals (DAC, BECCS, biochar) or offset retirements. Pfizer's stated path to net zero by 2040 emphasizes absolute reductions: 95% reduction in Scope 1 & 2 and 90% reduction in value chain emissions from a 2019 baseline. The company describes biodiversity site-level work and tree-planting (e.g., '175 Trees' project resulting in 600+ trees planted) as nature-positive initiatives but does not characterize these as carbon removals or quantify removal credits.

▾ expand

Primary: Manufacturing & R&D site energy efficiency

Reducing GHG emissions from manufacturing and R&D facilities is a key element of reaching net-zero by 2040. Pfizer invests in no- and low-carbon technologies, pursues LEED-certified facilities (NY HQ LEED Platinum, Ringaskiddy/Madrid LEED Gold, Vienna Platinum in 2024), and manages F-gases/refrigerants to limit ozone-depleting and high-GWP materials.

▾ expand

Primary: Fleet electrification (battery electric vehicles)

Pfizer's vehicle fleet, used largely by commercial teams to engage healthcare providers, accounted for ~12% of total Scope 1 GHG emissions in 2024. Pfizer is transitioning to battery electric vehicles (BEVs), with BEVs on the road in 10 markets and plans for additional markets in 2025+. Three electric vehicle tractors and charging stations deployed at Pleasant Prairie, Wisconsin logistics center.

▾ expand

Primary: Business travel emissions reduction

Target: reduce business travel emissions 25% by 2025 from a 2019 baseline. Travel-related GHG emissions in 2024 were 55% lower than the 2019 baseline (188 ktCO2e vs 421 ktCO2e). Pfizer has implemented digital tools to limit travel and uses preferred carriers advancing GHG targets.

▾ expand

Dependent: Supplier engagement on science-based targets

Scope 3 emissions are ~4x direct operations and procurement of goods and services is the largest contributor. Target: drive 64% of suppliers by spend to set science-based targets by 2025. Currently 65% of suppliers by spend have or have committed to develop SBTs (up 27% vs 2023). In 2024 Pfizer hosted PSCI annual meeting, ran a supplier summit, and launched a training academy for suppliers on measuring/reducing GHG emissions.

▾ expand

Dependent: Upstream logistics: air-to-ocean shift and biofuels

Target: reduce upstream transportation and distribution emissions 10% by 2025 from 2019. In 2024 emissions were 23% lower than the 2019 baseline and 40% lower than 2023. Pfizer's Ocean Program shifts shipments from air to ocean (up to 98% emission reduction per route) and expanded into Indonesia, Egypt, and Australia-to-US. In Europe, biofuels reduced truck shipment emissions by ~32% in 2024; sustainable aviation fuel cuts air emissions ~29%; ocean uses sustainable maritime fuels.

▾ expand

Primary: Sustainable packaging and product LCAs

Pfizer conducted 20+ life cycle assessments across small molecules, large molecules, vaccines, and medical devices. The Pfizer Clear digital tool estimates Scope 3 GHG emissions for packaging, devices, and single-use systems. Transitioning to electronic product information via 2D barcodes, exploring low-carbon aluminum, bio-based plastics, and recycled corrugated packaging.

▾ expand

Upstream transport methodology refined for logistics and tertiary packaging weights

Methodological enhancement to how logistics and tertiary packaging material weights are accounted for in upstream transportation; 2023 baseline restated 16% lower.

▾ expand

Added well-to-wheel (WTW) emissions to air business travel

Pfizer added well-to-wheel emissions for air travel to Scope 3 Category 6 in alignment with GHG Protocol. 2023 air travel emissions were restated upward by ~8%.

▾ expand

see 41 more events →

2023

sustainability report ↗cdp response ↗

Climate · carbon footprint (tCO2e)

Scope 1	617,404
Scope 2 (market-based)	490,632
Cat 1 · Purchased goods	3.4M
Cat 2 · Capital goods	126,588
Cat 3 · Fuel + energy	263,780
Cat 4 · Upstream transport	305,000
Cat 5 · Waste in operations	8,795
Cat 6 · Business travel	173,000
Cat 7 · Employee commuting	21,745
Cat 8 · Upstream leased	26,497
Cat 9 · Downstream transport	4,446
Cat 15 · Investments	6,754
Gross carbon footprint	—
Net carbon footprint	—

Energy (kWh)

Renewable electricity %

10%

Nature

water withdrawal m3	31.9Mm³
water consumption m3	3.8Mm³
waste hazardous t	79,900tonnes
waste generated t	114,800tonnes
waste recycled t	29,000tonnes
waste landfill t	85,800tonnes

Social

h s total recordable injury rate	0per 200000 hours
h s lost time injury rate	0per 200000 hours
h s fatalities	0count
employee turnover pct	6%
workforce board female pct	33%
supply chain audited pctⓘ	100%

Governance

audit assurance climate levelⓘ

1level

Events 2023· 22

Acquired Seagen Inc. in December 2023

Pfizer acquired Seagen Inc. in December 2023. Unless otherwise noted, KPIs in this report exclude data from Seagen. Future periods will integrate Seagen data, which will affect year-over-year comparability of nearly all metrics.

▾ expand

Net Zero by 2040 commitment (SBTi)

Pfizer aims to achieve the SBTi voluntary Net Zero standard by 2040, 10 years ahead of the standard's timeline. Commitment: 95% reduction in operational GHG and 90% in value-chain emissions from 2019 levels by 2040.

▾ expand

46% Scope 1+2 reduction by 2030 (1.5°C-aligned)

Pfizer's near-term SBTi-validated target: reduce Scope 1 and 2 GHG emissions by 46% from 2019 baseline by 2030, aligned with a 1.5°C trajectory, inclusive of 100% renewable electricity target.

▾ expand

100% renewable electricity by 2030 (RE100)

Pfizer is an RE100 member and targets 80% renewable electricity by 2025 and 100% by 2030, supported by virtual power purchase agreements (VPPAs) in North America and the EU.

▾ expand

25% business travel emissions reduction by 2025

Pfizer's 2025 goal: achieve a 25% reduction in business travel emissions from the 2019 baseline (288 thousand tCO2e target).

▾ expand

64% of suppliers (by spend) with science-based targets by 2025

Scope 3 supplier engagement goal: 64% of suppliers by spend committed to science-based GHG targets by 2025. Tracking began in 2021 (19%). Progress: 19% (2021) → 29% (2022) → 51% (2023).

▾ expand

Aligned upstream transport methodology with GLEC framework

In 2023, Pfizer aligned upstream transportation and distribution emissions methodology with the Global Logistics Emissions Council (GLEC) framework and expanded use of primary activity data. Methodology applied retroactively to historical estimates.

▾ expand

Added estimates for travel booked outside Pfizer's system

Pfizer added estimates to 2019-2023 business travel results to account for travel booked outside Pfizer's travel system (~10% of total business travel emissions). Improves completeness of disclosure.

▾ expand

Primary: Sustainable science & life-cycle assessments

Pfizer is conducting representative LCAs for small molecules, large molecules, vaccines, and devices to identify highest-impact reduction opportunities, and is developing sustainable product-design principles across R&D. Participating in a consortium with NHS England to develop a sector-wide LCA standard for pharmaceuticals.

▾ expand

Reports alignment with UN SDGs 3, 5, 8, 9, 10, 12, 13, 16, 17

Pfizer aligns its reporting with multiple UN Sustainable Development Goals across the GRI Index: SDG 3 (Good Health), 5 (Gender Equality), 8 (Decent Work), 9 (Industry & Innovation), 10 (Reduced Inequalities), 12 (Responsible Consumption), 13 (Climate Action), 16 (Peace, Justice, Strong Institutions), 17 (Partnerships).

▾ expand

see 12 more events →

2022

annual report ↗cdp response ↗sustainability report ↗

Climate · carbon footprint (tCO2e)

Scope 1	650,587
Scope 2 (market-based)	475,107
Scope 3	9.7M
Cat 1 · Purchased goods	8.2M
Cat 2 · Capital goods	282,414
Cat 3 · Fuel + energy	262,990
Cat 4 · Upstream transport	712,300
Cat 5 · Waste in operations	8,701
Cat 6 · Business travel	80,200
Cat 7 · Employee commuting	38,557
Cat 8 · Upstream leased	30,449
Cat 9 · Downstream transport	8,351
Cat 10 · Processing of sold	0
Cat 11 · Use of sold products	0
Cat 12 · End-of-life	0
Cat 13 · Downstream leased	0
Cat 14 · Franchises	0
Cat 15 · Investments	6,939
Gross carbon footprint	10.8M
Offsets retired	-0
Net carbon footprint	10.8M

Energy (kWh)

Electricity	1.2B
Fuel (stationary + mobile)	3.1B
Heat / steam	211.7M
Total energy	4.6B
Renewable energy	(166.7M)
Non-renewable / hydrocarbon	4.4B
Renewable electricity %	8%

Nature

water withdrawal m3	28.8Mm³
water consumption m3	4Mm³
waste hazardous t	75,700tonnes
waste generated t	110,800tonnes
waste recycled t	26,000tonnes
waste landfill t	84,800tonnes

Social

h s total recordable injury rate	0per 200000 hours
h s lost time injury rate	0per 200000 hours
h s fatalities	0count
employee turnover pct	7%
workforce board female pct	33%
workforce management female pct	43%
ethnicity minority pct	28%
gender pay gap median pct	-1%

Governance

internal carbon price usd per tco2eⓘ	20USD per tCO2e
audit assurance climate levelⓘ	2scale 0-2
esg linked executive pay yn	1yn
board diversity pct	25%
board independence pct	92%

P&L highlights (USD)

Headcount (FTE)	83,000people
Revenue	100.3B
Cost of revenue	(38.2B)
Gross profit	62.1B
Operating expenses (S&M + G&A)	(24.5B)
Operating income	37.5B
Net income	31.4B

Balance sheet highlights (USD)

Property, plant & equipment	16.3B
Total assets	197.2B
Total debt	34.9B
Cash & equivalents	416M
Minority interest	256M

Market & shares

Market cap (FY-end)	287.4B
Shares outstanding	5.6B

Events 2022· 71

Planned carbon removal strategy for hard-to-abate residual emissions at 2040 net-zero target date

While Pfizer's primary focus is driving absolute GHG reductions across its value chain to achieve net-zero by 2040, the company anticipates that a carbon removal strategy may be necessary to address hard-to-abate emissions as it progresses towards the target end dates. Pfizer has stated it intends to neutralise unabated emissions with permanent carbon removals at the target year but has not yet specified removal technology or volumes. No carbon removals, offsets or credits were retired in the reporting year.

▾ expand

Net Zero by 2040 ambition

In 2022, Pfizer announced aim to achieve the voluntary Net Zero Standard by 2040, ten years earlier than the standard's timeline. Targets: 46% Scope 1+2 reduction by 2030; 95% Scope 1+2 reduction by 2040; 90% value chain reduction by 2040; 100% renewable electricity by 2030 (80% by 2025).

▾ expand

Upgraded to reasonable assurance for 2021-2022 GHG data

2019 GHG data verified to limited assurance level by ERM-CVS; 2021-2022 data upgraded to reasonable assurance. Verification of 2023 data in progress at time of report publication.

▾ expand

Long-term Scope 1+2 target: 95% reduction by 2040 vs 2019

Pfizer set Abs 6: 95% reduction in Scope 1+2 emissions by 2040 from 2019 baseline, aligned with Net-Zero Standard. As of end 2024, 15.63% achieved (15% reduction from baseline).

▾ expand

Long-term Scope 3 target: 90% reduction by 2040 vs 2019

Pfizer set Abs 7: 90% absolute reduction in Scope 3 emissions (all relevant categories) by 2040 from 2019 baseline. As of end 2024, -15.61% achieved (Scope 3 increased from base year due to Seagen acquisition and methodology changes).

▾ expand

Net-Zero 2040 target committed (NZ1)

Pfizer committed to achieving the voluntary Net-Zero Standard by 2040, ten years earlier than the standard's timeline, covering Scopes 1, 2, and 3. Target covers at least 95% of S1+S2 and at least 90% of S3. Intends to neutralize residual emissions with permanent carbon removals.

▾ expand

Net-Zero by 2040 commitment

In June 2022, Pfizer CEO committed to accelerate decarbonization of value chain, aiming to achieve SBTi voluntary Net-Zero Standard by 2040, including 90% absolute reduction in value chain emissions from 2019 baseline. Submission to SBTi planned for 2023.

▾ expand

Added US Fleet personal vehicle use to Scope 3 business travel

Expanded boundary for Scope 3 Business Travel to include use of personal vehicles for business by US Fleet colleagues, applied retroactively to 2019-2022.

▾ expand

Revised methodology for upstream transport emissions

Revised methodology for calculating Scope 3 Upstream Transportation & Distribution emissions to more accurately capture source data; applied to 2019-2022 calculations.

▾ expand

Baseline restated for acquisitions, divestitures, closures

Pfizer's reporting boundary was baseline-adjusted per GHG Protocol to reflect acquisitions (San Diego, San Francisco R&D sites), divestitures (Adelaide, Australia; Valencia, Venezuela), and site closures.

▾ expand

see 61 more events →

2021

sustainability report ↗annual report ↗cdp response ↗

Climate · carbon footprint (tCO2e)

Scope 1	662,438
Scope 2 (market-based)	519,558
Cat 1 · Purchased goods	3.4M
Cat 2 · Capital goods	251,040
Cat 3 · Fuel + energy	269,938
Cat 4 · Upstream transport	672,600
Cat 5 · Waste in operations	9,164
Cat 6 · Business travel	29,000
Cat 7 · Employee commuting	56,832
Cat 8 · Upstream leased	29,452
Cat 9 · Downstream transport	12,969
Cat 10 · Processing of sold	0
Cat 11 · Use of sold products	0
Cat 12 · End-of-life	0
Cat 13 · Downstream leased	0
Cat 14 · Franchises	0
Cat 15 · Investments	36,178
Gross carbon footprint	—
Offsets retired	(2,533)
Net carbon footprint	—

Energy (kWh)

Electricity	1.2B
Fuel (stationary + mobile)	3.2B
Heat / steam	204M
Total energy	4.5B
Renewable energy	(177.4M)
Non-renewable / hydrocarbon	4.4B
Renewable electricity %	7%

Nature

water withdrawal m3	27.5Mm³
water consumption m3	4Mm³
waste hazardous t	82,700tonnes
waste generated t	122,800tonnes
waste recycled t	43,500tonnes
waste landfill t	78,800tonnes

Social

workforce board female pct	33%
employee turnover pct	7%
h s total recordable injury rate	0per 200000 hours
h s lost time injury rate	0per 200000 hours
h s fatalities	0count
workforce management female pct	42%
ethnicity minority pct	25%
workforce female pct	48%
gender pay gap median pct	8%

Governance

audit assurance climate levelⓘ	2scale
internal carbon price usd per tco2eⓘ	20USD per tCO2e
esg linked executive pay yn	1yn
board diversity pct	33%

P&L highlights (USD)

Headcount (FTE)	79,000people
Revenue	81.3B
Cost of revenue	(34.4B)
Gross profit	46.9B
Operating expenses (S&M + G&A)	(26.1B)
Operating income	20.8B
Net income	22.1B

Balance sheet highlights (USD)

Property, plant & equipment	14.9B
Total assets	181.5B
Total debt	37B
Cash & equivalents	1.9B
Minority interest	262M

Market & shares

Market cap (FY-end)	330.7B
Shares outstanding	5.6B

Events 2021· 46

Kalamazoo coal boilers retired

In early 2021 Pfizer concluded a three-year project to replace and remove six coal-fired boilers at the Kalamazoo, Michigan manufacturing site. Eliminates 10,800 mT CO2e of GHG emissions, 208 tons of non-GHG emissions, and 1,550 tons of coal ash annually.

▾ expand

SBTi 1.5°C-aligned targets approved

Pfizer's fourth-generation GHG emission reduction targets were approved by the Science Based Targets initiative (SBTi) in February 2021 as aligned with a 1.5°C trajectory. Commitments: reduce Scope 1+2 by 46% from 2019 baseline by 2030; 80% renewable electricity by 2025 and 100% by 2030; reduce upstream transport by 10% and business travel by 25% by 2025; 64% of suppliers by spend to set SBT by 2025.

▾ expand

Alignment with SDGs 3, 5, 6, 7, 8, 9, 10, 12, 13, 16, 17

Pfizer aligns reporting and use-of-proceeds with UN Sustainable Development Goals: SDG 3 (Good Health), SDG 5 (Gender Equality), SDG 6 (Clean Water), SDG 7 (Affordable Clean Energy), SDG 8 (Decent Work), SDG 9 (Industry/Innovation/Infrastructure), SDG 10 (Reduced Inequalities), SDG 12 (Responsible Consumption), SDG 13 (Climate Action), SDG 16 (Peace, Justice), SDG 17 (Partnerships).

▾ expand

CDP Supplier Engagement Leader 4th consecutive year

Pfizer recognized as CDP Supplier Engagement Leader for the fourth consecutive year for work to measure and reduce environmental risks in supply chain.

▾ expand

Initiated reporting of upstream transport emissions

2021 was first year Pfizer reported upstream transportation & distribution carbon emissions (672.6 thousand tCO2e). COVID-19 vaccine transported predominantly by air using cold chain technologies drove an increase in logistics emissions.

▾ expand

Patients Treated KPI methodology consolidated

In 2020 ESG report two metrics (Patients Treated 420+ million and Patients Reached 58+ million) were reported separately. In 2021 these were combined into a single KPI; 2020 was restated to 399 million patients treated under new methodology.

▾ expand

2025 Opportunity Parity Goals

By 2025: achieve 47% women globally at VP+ level; achieve parity at VP+ for US minorities by increasing representation from 19% to 32% and doubling underrepresented African American/Black and Hispanic/Latino populations.

▾ expand

ESG Scorecard linked to executive pay

Effective 2022 performance year, Compensation Committee adopted ESG Scorecard for short-term incentive plan funding affecting 30,000+ colleagues. ESG metrics: women VP+ globally, US minorities VP+, and GHG emissions. Also included ESG KPI-linked metrics in $7B 5-year revolving credit facility.

▾ expand

Acquisitions of Trillium and Arena Pharmaceuticals

Acquired Trillium Therapeutics Inc. (lead molecule TTI-622) in 2021 and announced acquisition of Arena Pharmaceuticals for immuno-inflammatory disease portfolio.

▾ expand

Path to 100% renewable electricity by 2030 via VPPAs and RECs

Pfizer committed to RE100 with 80% renewable electricity by 2025 and 100% by 2030. In October 2021 entered a 15-year virtual PPA with Vesper Energy for 310 MW of solar from the Hornet Solar project in west Texas starting 2023, effectively covering North American purchased electricity (~50% of global use). Working to establish a virtual PPA in Europe (~16% of global electricity) and securing RECs for the remainder by 2025. Sourced 6.5% renewable electricity in 2021.

▾ expand

see 36 more events →

2020

sustainability report ↗

Climate · carbon footprint (tCO2e)

Scope 1	654,460
Scope 2 (market-based)	542,521
Scope 3	3.8M
Cat 1 · Purchased goods	2.5M
Cat 2 · Capital goods	191,894
Cat 3 · Fuel + energy	203,093
Cat 4 · Upstream transport	723,558
Cat 5 · Waste in operations	14,940
Cat 6 · Business travel	96,300
Cat 7 · Employee commuting	48,414
Cat 8 · Upstream leased	30,522
Cat 9 · Downstream transport	7,295
Cat 10 · Processing of sold	0
Cat 11 · Use of sold products	0
Cat 12 · End-of-life	0
Cat 13 · Downstream leased	0
Cat 14 · Franchises	0
Cat 15 · Investments	36,839
Gross carbon footprint	5M
Offsets retired	(2,533)
Net carbon footprint	5M

Energy (kWh)

Electricity	1.2B
Fuel (stationary + mobile)	3.1B
Heat / steam	193.4M
Total energy	4.5B
Renewable energy	(127.9M)
Non-renewable / hydrocarbon	4.4B
Renewable electricity %	5%

Nature

water withdrawal m3	14.1Mm³
water consumption m3	3.8Mm³
waste hazardous t	114,000tonnes
waste generated t	103,360tonnes
waste recycled t	59,900tonnes

Social

workforce female pct	47%
workforce management female pct	38%
employee turnover pct	5%
h s total recordable injury rate	0per 200000 hours
h s lost time injury rate	0per 200000 hours
h s fatalities	0count
workforce board female pct	33%
ethnicity minority pct	22%
gender pay gap median pct	0%
supply chain audited pctⓘ	90%

Governance

audit assurance climate levelⓘ	1level
internal carbon price usd per tco2eⓘ	20USD per tCO2e
esg linked executive pay yn	1yn
board diversity pct	58%

P&L highlights (USD)

Headcount (FTE)	78,500people
Revenue	41.9B
Cost of revenue	(11.8B)
Gross profit	30.1B
Operating expenses (S&M + G&A)	(20.8B)
Operating income	9.1B
Net income	9.2B

Balance sheet highlights (USD)

Property, plant & equipment	13.7B
Total assets	154.2B
Total debt	38.3B
Cash & equivalents	1.8B
Minority interest	235M

Market & shares

Market cap (FY-end)	204.5B
Shares outstanding	5.6B

Events 2020· 51

SBTi-validated 46% Scope 1+2 reduction target by 2030 (Abs 3)

Pfizer set a 1.5°C-aligned absolute Scope 1+2 GHG reduction target of 46% by 2030 from a 2019 base year, approved by the Science Based Targets initiative in 2020. Base year emissions: Scope 1 702,830 tCO2e, Scope 2 (market) 586,432 tCO2e.

▾ expand

100% renewable electricity by 2030 as part of carbon-neutral pathway

Pfizer committed in December 2020 to procure 100% renewable energy by 2030 across internal operations, with a 46% absolute reduction in Scope 1+2 emissions from a 2019 baseline. The 2030 target is SBTi-validated as 1.5°C-aligned. Any remaining residual emissions will be offset through carbon credits. Specific PPA/REC procurement instruments are not disclosed in this report.

▾ expand

2030 carbon neutral commitment with 46% absolute Scope 1+2 reduction from 2019 baseline (SBTi 1.5°C validated)

Pfizer committed to become carbon neutral across internal operations by 2030, including a 46% absolute reduction in Scope 1 and 2 emissions from a 2019 baseline and 100% renewable energy procurement. Any remaining emissions to be offset via carbon credits. SBTi commended this as an ambitious 1.5°C-aligned target.

▾ expand

2025 value-chain reduction targets: 10% upstream logistics, 25% business travel

By 2025, Pfizer aims to reduce upstream logistics emissions by 10% and business travel emissions by 25% from a 2019 baseline.

▾ expand

Upjohn spin-off and merger with Mylan to form Viatris

On November 16, 2020, Pfizer's Upjohn business (off-patent branded and generics) was spun off and combined with Mylan to create Viatris. ESG metrics generally exclude Upjohn going forward, though environmental metrics include Upjohn for continuity with 2012-baseline 2020 goals. This affects year-over-year comparability of social metrics.

▾ expand

Alignment with UN SDGs 3, 5, 8, 9, 10, 13, 17

Pfizer reports alignment with UN Sustainable Development Goals 3 (Good Health), 5 (Gender Equality), 8 (Decent Work), 9 (Industry/Innovation), 10 (Reduced Inequalities), 12 (Responsible Consumption), 13 (Climate Action), 16 (Peace/Justice), and 17 (Partnerships).

▾ expand

$1.25bn Sustainability Bond — first biopharma sustainability bond

In March 2020 Pfizer issued the first biopharmaceutical Sustainability Bond ($1.25bn, 2.625% coupon, due April 2030). As of Dec 31 2020, $43m of net proceeds allocated to environmental projects and $253m to social projects (including replenishing Pfizer Foundation endowment, women's health, AMR, and health infrastructure).

▾ expand

Carbon neutral by 2030 ambition announced

In December 2020 Pfizer announced its ambition to become carbon neutral across internal operations by 2030, with remaining emissions addressed through high-quality and verifiable offsets.

▾ expand

CDP Supplier Engagement Leaderboard 2020 (3rd consecutive year)

Pfizer named to CDP's 2020 Supplier Engagement Leaderboard for the third consecutive year (2018, 2019, 2020) and featured in CDP's Stories of Change.

▾ expand

2025 opportunity parity goals: 47% female VP+, 32% U.S. minority VP+

Pfizer set 2025 targets to reach 47% global female representation at VP+ (from 38.1% in 2020) and 32% U.S. minority representation at VP+ (from 21.5% in 2020), including doubling of African American/Black and Hispanic/Latino representation.

▾ expand

see 41 more events →